Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.36 |
| ▸ | FEN1 | P39748 | 7/20 | 0.36 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18015528 | 0.91 | RAB9A (0.38) | HPGDSALOX5APFEN1NPC1RAB9A | |
| SCHEMBL11976419 | 0.87 | LDHA (0.44) | HPGDSNPC1RAB9ALDHABAZ2B | |
| SCHEMBL21662276 | 0.87 | TRPV1 (0.39) | HPGDSRAB9A | |
| SCHEMBL19794512 | 0.86 | HPGDS (0.36) | HPGDSALOX5APFEN1NPC1RAB9A | |
| SCHEMBL19794507 | 0.85 | ALOX5AP (0.33) | HPGDSALOX5APFEN1NPC1RAB9A | |
| SCHEMBL19794513 | 0.85 | MEN1 (0.40) | HPGDSALOX5APFEN1NPC1RAB9A | |
| SCHEMBL19794491 | 0.85 | NPC1 (0.42) | HPGDSALOX5APFEN1NPC1RAB9A | |
| SCHEMBL19794503 | 0.84 | FEN1 (0.32) | HPGDSALOX5APFEN1LDHA | |
| SCHEMBL19794492 | 0.84 | KDM4E (0.41) | HPGDSALOX5APFEN1NPC1RAB9A | |
| SCHEMBL18015715 | 0.81 | LMNA (0.38) | HPGDSALOX5APFEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | HPGDS 4832/4885ALOX5AP 3447/4885FEN1 1267/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | HPGDS 4844/4885ALOX5AP 4001/4885FEN1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.